Drug Profile
Belnacasan
Alternative Names: UNII-00OLE78529; VX-765Latest Information Update: 24 Mar 2018
Price :
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Epilepsy; Inflammation; Psoriasis
Most Recent Events
- 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)
- 02 Dec 2011 Adverse events and efficacy data from a phase II trial in Epilepsy presented at the 65th Annual Meeting of the American Epilepsy Society (AES-2011)
- 10 Mar 2011 Efficacy and adverse events data from a phase II trial in Partial epilepsies released by Vertex Pharmaceuticals